Avadel Pharmaceuticals plc announced the appointment of Mark McCamish to its board of directors, effective December 10, 2019. Dr. McCamish is an internationally recognized expert in drug development and manufacturing. He is currently the President and Chief Executive Officer of Forty Seven Inc. immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer. Prior to Forty Seven Inc., Dr. McCamish was the Global Head of Biopharmaceutical Development at Sandoz International, a Novartis company. Dr. McCamish was acknowledged by Novartis with a Chairman award for 2010, 2011, 2012, 2013, 2014, and 2015, and the European Antibody Congress named Dr. McCamish one of the top 50 global antibody industry influencers.